ANSWER: C

Rationale:

M.R.'s clinical profile creates several intersecting constraints that narrow the appropriate second agent choice. Her potassium of 4.8 mEq/L on losartan alone in the setting of CKD and diabetes is borderline elevated — adding any potassium-retaining agent (spironolactone) or escalating RAAS blockade carries meaningful hyperkalemia risk. Amlodipine addresses all constraints simultaneously: it is highly effective in Black patients through a renin-independent vascular mechanism that does not depend on RAAS activity (important given her low-renin physiology); it requires no renal dose adjustment at any eGFR (hepatic elimination); it has no effect on potassium; and the CCB plus RAAS inhibitor combination has strong evidence from ACCOMPLISH for cardiovascular event reduction in high-risk hypertensive patients. A thiazide diuretic would also be guideline-supported but the borderline potassium in this specific metabolic context makes amlodipine the safer initial choice. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect because spironolactone with potassium already at 4.8 mEq/L on an ARB in a patient with CKD and diabetes creates significant hyperkalemia risk; spironolactone is appropriate as a fourth-line agent.
• Option B: Option B is incorrect because blanket thiazide preference in Black patients does not override the metabolic safety concern in this specific patient with borderline potassium on RAAS inhibition and CKD.
• Option D: Option D is incorrect because non-DHP CCBs do not have an established specific renoprotective mechanism through negative chronotropy in diabetic nephropathy, and verapamil carries significant drug interaction and tolerability concerns.
• Option E: Option E is incorrect because thiazide-type diuretics retain adequate efficacy at eGFR 52; loop diuretics are needed when eGFR falls below approximately 30 mL/min/1.73m2.

ANSWER: A

Rationale:

CCB-associated peripheral edema arises from preferential arteriolar dilation — amlodipine dilates resistance arterioles more than venous capacitance vessels. Capillary hydrostatic pressure rises in dependent tissues and fluid accumulates in the interstitium. This is not sodium-mediated volume overload (BNP is normal, no systemic volume expansion), which is why loop diuretics have limited efficacy for this specific edema type. Since losartan is already at maximum dose (100 mg), the primary pharmacological options are: (1) reducing amlodipine from 10 mg to 5 mg — the edema is dose-dependent and reducing arteriolar dilation directly reduces the hydrostatic pressure imbalance; or (2) switching to felodipine, which has higher vascular selectivity than amlodipine and produces less peripheral edema at equivalent antihypertensive doses in comparative data. Maintaining the RAAS inhibitor at maximum dose is important because it provides efferent arteriolar dilation and venodilation that partially counteracts the CCB edema mechanism. Her potassium of 4.9 mEq/L reinforces against adding potassium-retaining agents. Option B: Option C: Option D: Option E:

• Option B: Option B is incorrect because losartan does not cause sodium retention; RAAS inhibition reduces, not increases, sodium retention.
• Option C: Option C is incorrect because CCB edema is hemodynamic (capillary hydrostatic pressure), not lymphatic obstruction; it does not require mandatory CCB discontinuation when pharmacological alternatives are available.
• Option D: Option D is incorrect because the normal BNP essentially excludes significant heart failure decompensation; the edema mechanism is vascular, not cardiac.
• Option E: Option E is incorrect because the edema is not caused by RAAS inhibition-mediated sodium retention; the mechanism is amlodipine's arteriolar dilation.

ANSWER: C

Rationale:

The chlorthalidone-losartan combination has no pharmacokinetic interaction. The primary clinically important pharmacodynamic consideration is potassium balance: chlorthalidone causes kaliuresis (potassium wasting through increased collecting duct sodium delivery and aldosterone-mediated potassium secretion), while losartan blunts aldosterone secretion and thereby partially offsets this potassium loss. In practice, the combination of a thiazide plus an ARB often results in a near-neutral potassium effect in patients with normal renal function, but this is not guaranteed — the net effect depends on dose, dietary intake, and individual renin-aldosterone dynamics. Given M.R.'s baseline potassium of 4.7 mEq/L in the context of CKD and diabetes, the thiazide will likely bring potassium toward or into the normal range, but hypokalemia is also possible. Electrolytes should be checked at 2 weeks. Additionally, there is a modest pharmacodynamic complementarity: chlorthalidone-driven volume depletion activates the RAAS, increasing the angiotensin II substrate available for losartan to block, which can enhance ARB antihypertensive efficacy.

ANSWER: B

Rationale:

The rationale for adding finerenone to M.R.'s regimen is cardiorenal protection in type 2 diabetes with CKD and persistent albuminuria (UACR 94 mg/g — still above the 30 mg/g threshold) on maximally tolerated background RAAS inhibition. FIDELIO-DKD demonstrated that finerenone significantly reduced a composite of kidney failure, sustained eGFR decline of at least 40%, and renal death compared to placebo in patients with type 2 diabetes, CKD, and albuminuria on RAAS inhibitor therapy. FIGARO-DKD demonstrated reduction in cardiovascular mortality and non-fatal MI, stroke, and HF hospitalization. These benefits occur through finerenone's anti-inflammatory and antifibrotic effects on MR blockade in the kidney and cardiovascular system — distinct from and additive with RAAS inhibition's hemodynamic renoprotection. The critical monitoring parameter is potassium: current guidelines require potassium ≤4.8 mEq/L before initiation (M.R.'s is 4.1 mEq/L — appropriate) and monitoring at 4 weeks given the combination of RAAS inhibition, CKD, and an MRA. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect because finerenone is not a diuretic replacement for chlorthalidone; it does not provide equivalent volume control and serves a different pharmacological purpose.
• Option C: Option C is incorrect because finerenone's evidence base in this context is cardiorenal protection from FIDELIO-DKD and FIGARO-DKD, not primarily antihypertensive efficacy; PATHWAY-2 evidence applies to spironolactone in resistant hypertension.
• Option D: Option D is incorrect because finerenone does not replace CCBs; its vascular effects do not substitute for arteriolar vasodilation.
• Option E: Option E is incorrect because spironolactone is not absolutely contraindicated in CKD stage 3a; the preference for finerenone is based on superior evidence and lower hyperkalemia risk, not on an absolute contraindication. CASE 2 — P.T. is a 74-year-old man with isolated systolic hypertension (BP 178/64 mmHg; pulse pressure 114 mmHg). He has no history of heart failure, coronary artery disease, diabetes, or CKD (eGFR 74 mL/min/1.73m²). He is on no antihypertensive therapy. Resting heart rate is 76 bpm.

ANSWER: E

Rationale:

Isolated systolic hypertension in the elderly is the archetypal vascular stiffness disorder. The Windkessel mechanism — the aorta's ability to buffer each systolic ejection by distending its walls and then releasing stored energy during diastole — depends on arterial wall compliance. With aging, elastin fragmentation and increased collagen cross-linking stiffen the aortic wall. Each systolic ejection is no longer cushioned by wall distension; instead, the pressure wave propagates rapidly through the stiff aorta, raising systolic pressure. Diastolic pressure falls or normalizes because the stored energy return to maintain diastolic pressure is lost. Pulse wave velocity increases and pulse pressure widens. Cardiac output in elderly patients with ISH is typically normal or modestly reduced — not elevated. Beta-blockers, which reduce cardiac output and heart rate, do not address the peripheral vascular resistance that DHP CCBs reduce, and may worsen diastolic pressure in patients with stiff arteries. Long-acting DHP CCBs (nitrendipine in Syst-Eur, reducing stroke 42% in ISH) and thiazide-type diuretics (chlorthalidone in SHEP, indapamide in HYVET) have the strongest evidence base in ISH because they address peripheral arteriolar resistance and produce sustained vascular effects. Option A: Option B: Option C: Option D:

• Option A: Option A is incorrect because ISH is not primarily driven by renal sodium retention; it is a vascular stiffness disorder.
• Option B: Option B is incorrect because ISH is not caused by sympathetic overactivation of cardiac output; cardiac output is normal or reduced.
• Option C: Option C is incorrect because ISH is not caused by peripheral arterial narrowing preventing diastolic rebound; it is aortic stiffness-related.
• Option D: Option D is incorrect because ISH is not caused by polycythemia or plasma viscosity.

ANSWER: C

Rationale:

The J-curve in isolated systolic hypertension — the concern that excessive diastolic BP lowering may harm coronary perfusion — is real but the threshold for clinical harm is generally estimated at approximately 55–65 mmHg in available trial data, with most analyses suggesting the risk increases substantially below 60 mmHg. At 60 mmHg P.T. is right at the edge of this threshold. The appropriate response is not to stop therapy — he remains 22 mmHg above systolic target with significant stroke, heart failure, and cognitive risk from sustained systolic hypertension. Titrating amlodipine to 10 mg with close monitoring is a reasonable next step: amlodipine preferentially reduces peripheral arteriolar resistance and systolic pressure in ISH, and long-acting DHP CCBs have the strongest evidence in elderly ISH (Syst-Eur). The critical clinical instruction is to monitor for symptoms of coronary underperfusion (new angina, dyspnea on exertion) and to reassess BP targets if diastolic falls below 55–60 mmHg on the higher dose. Option D is not wrong — adding a second agent is reasonable — but C is more pharmacologically complete in explaining the J-curve threshold reasoning. Option A: Option B: Option E:

• Option A: Option A is incorrect because a diastolic of 60 mmHg with systolic of 162 mmHg is not an absolute contraindication to therapy — the benefit of systolic reduction substantially outweighs the diastolic concern at this threshold.
• Option B: Option B is incorrect because beta-blockers do not selectively lower systolic without affecting diastolic in ISH; they may lower diastolic further and are not the preferred agents in elderly ISH with stiff arteries.
• Option E: Option E is incorrect because verapamil does not selectively lower systolic over diastolic in ISH through an established mechanism.

ANSWER: E

Rationale:

In a 74-year-old man on amlodipine 10 mg who is now being started on chlorthalidone, the two most important adverse effects to monitor are hyponatremia and orthostatic hypotension. Hyponatremia: elderly patients have reduced total body water, making any given degree of sodium loss produce a larger proportional fall in serum sodium; age-related increases in ADH sensitivity further impair free water excretion; chlorthalidone's long half-life (40–60 hours) sustains these effects longer than HCTZ; sodium should be checked at 2–4 weeks. Orthostatic hypotension: the combination of thiazide-induced volume contraction (reducing preload) and amlodipine-induced arteriolar vasodilation (reducing afterload and venous tone) creates additive risk of postural hypotension, particularly dangerous in elderly patients at risk for falls. Assess orthostatic BP at each follow-up visit. Option A: Option B: Option C: Option D:

• Option A: Option A is incorrect because thiazides cause hypokalemia (potassium wasting), not hyperkalemia; elderly patients are at greater risk of hypokalemia and hyponatremia, not potassium retention.
• Option B: Option B is incorrect because gout does not develop in all elderly patients on thiazide diuretics within 8 weeks; prophylactic allopurinol is not standard practice.
• Option C: Option C is incorrect because chlorthalidone does not cause arteriolar dilation; peripheral edema is a CCB adverse effect, not a thiazide adverse effect.
• Option D: Option D is incorrect because urinary incontinence from thiazide natriuresis overwhelming bladder capacity is not an established adverse effect requiring immediate discontinuation.

ANSWER: C

Rationale:

Dietary sodium restriction (target less than 2 g/day of sodium, or approximately 5 g/day of salt) reduces blood pressure through volume and RAAS effects; in a patient on a thiazide diuretic, sodium restriction also enhances the diuretic response by reducing compensatory proximal tubular sodium reabsorption that limits NCC transporter delivery — the diuretic and dietary sodium restriction work synergistically. The expected BP reduction from sodium restriction alone is 4–8 mmHg systolic in patients with hypertension. Alcohol restriction to less than 2 standard drinks per day reduces systolic BP by approximately 4–6 mmHg. Regular aerobic exercise, modest weight loss, and the DASH diet all contribute additional systolic BP reductions of 4–8 mmHg each. For P.T. at 138/60 mmHg, these lifestyle measures could plausibly allow dose reduction, though complete drug discontinuation in established ISH is unlikely given the structural vascular pathophysiology. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect because dietary sodium restriction is not contraindicated in elderly patients on thiazide diuretics; with close monitoring, sodium restriction is safe and pharmacologically beneficial in this combination.
• Option B: Option B is incorrect because aerobic exercise lowers rather than raises resting BP; acute exercise-induced BP elevation does not negate the long-term antihypertensive benefit of a regular exercise program.
• Option D: Option D is incorrect because weight loss does meaningfully reduce systolic blood pressure even in elderly patients with ISH; adipose tissue-related hemodynamic effects (sympathetic activation, RAAS upregulation) contribute to hypertension in overweight elderly patients.
• Option E: Option E is incorrect because all of the mentioned lifestyle modifications — sodium restriction, exercise, alcohol reduction, and the DASH diet — have evidence supporting BP reduction in hypertensive patients including elderly patients. CASE 3 — R.K. is a 61-year-old man with hypertension, heart failure with reduced ejection fraction (HFrEF; EF 32%), and permanent atrial fibrillation. Current medications: carvedilol 25 mg twice daily, sacubitril/valsartan 97/103 mg twice daily, spironolactone 25 mg daily, furosemide 40 mg daily. BP is 158/92 mmHg. Heart rate is 74 bpm.

ANSWER: B

Rationale:

In R.K.'s complex regimen, every additional agent must satisfy multiple constraints simultaneously. He is on carvedilol (a beta-blocker), which absolutely precludes adding any non-DHP CCB — verapamil or diltiazem — because both produce additive AV nodal suppression (severe bradycardia, heart block risk) and additive negative inotropy in HFrEF. His HFrEF (EF 32%) independently contraindicates verapamil and diltiazem through negative inotropic harm. His potassium of 4.5 mEq/L on sacubitril/valsartan and spironolactone is manageable but caution is needed — no additional potassium-raising agents. Amlodipine is the single agent satisfying all constraints: V-HeFT III established it as hemodynamically neutral in HFrEF (no worsening of EF, hospitalization, or mortality); it combines safely with carvedilol (DHP CCBs do not suppress AV conduction or further reduce contractility); no potassium effect; no renal dose adjustment. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect because verapamil is doubly contraindicated — HFrEF (negative inotropy) and combination with carvedilol (additive AV nodal suppression); sacubitril/valsartan does not attenuate negative inotropy from non-DHP CCBs.
• Option C: Option C is incorrect for the same fundamental reasons — diltiazem is contraindicated in HFrEF and with beta-blockers.
• Option D: Option D is incorrect because adding a second beta-blocker (bisoprolol) on top of carvedilol provides no additional HFrEF benefit and risks excessive bradycardia; the guideline approach is to optimize a single beta-blocker.
• Option E: Option E is incorrect because adding chlorthalidone to furosemide creates a dual diuretic combination that risks excessive volume depletion, electrolyte disturbance, and renal impairment — not a standard antihypertensive approach in compensated HFrEF without volume overload.

ANSWER: C

Rationale:

Distinguishing CCB-associated peripheral edema from HF decompensation in a patient with chronic HFrEF is a clinically important challenge. CCB-associated edema is a hemodynamic phenomenon — it arises from preferential arteriolar dilation raising capillary hydrostatic pressure in dependent tissues without systemic volume expansion. It does not typically drive substantial BNP elevation. In contrast, HF decompensation with true volume overload produces progressive BNP elevation, orthopnea, increasing dyspnea, weight gain, and worsening functional capacity. In R.K., the key distinguishing features favoring CCB edema are: the modest BNP rise (280 to 340 pg/mL) without proportionate clinical deterioration; the temporal association with amlodipine; and the absence of other decompensation markers. A BNP rise of this magnitude in a patient with chronic HFrEF may represent normal variability (BNP fluctuates 30–50% in stable HF patients without clinical decompensation). The appropriate response is clinical assessment — weight, orthopnea history, exercise tolerance — rather than automatic amlodipine discontinuation or escalation of diuretic therapy. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect because bilateral distribution does not distinguish HF from CCB edema — CCB-associated edema characteristically affects both lower extremities symmetrically.
• Option B: Option B is incorrect because CCB-associated edema does not exclude any BNP elevation; modest BNP rises can occur in stable HFrEF patients without true decompensation and are not pathognomonic of fluid overload.
• Option D: Option D is incorrect because CCB-associated edema typically develops over weeks, not within 72 hours; delayed onset is common and not indicative of cardiac decompensation.
• Option E: Option E is incorrect because stable potassium is not pathognomonic of CCB edema; HF decompensation does not invariably cause potassium elevation.

ANSWER: C

Rationale:

Adding a second RAAS inhibitor (ACEi or ARB) to sacubitril/valsartan — which already provides full AT1 receptor blockade through its valsartan component — is contraindicated. This represents dual RAAS blockade, which ONTARGET established increases risks of AKI, hyperkalemia, and symptomatic hypotension without providing cardiovascular benefit over monotherapy in patients with vascular disease or diabetes. In HFrEF patients on sacubitril/valsartan who already have relative hypotension risk and often impaired renal autoregulation, adding another RAAS inhibitor compounds these risks substantially. The sacubitril/valsartan prescribing information and HFrEF guidelines explicitly contraindicate concurrent ACEi or ARB use. The appropriate strategy for additional blood pressure control in this patient is a different mechanism — such as maintaining the amlodipine at a tolerated dose, adding a diuretic if volume management allows, or reassessing BP targets given the HFrEF context. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect because ONTARGET demonstrated the opposite — dual RAAS blockade increased adverse events without benefit over monotherapy.
• Option B: Option B is incorrect because ARBs do not have distinct receptor subtype profiles that complement each other; adding a second ARB to sacubitril/valsartan provides no additional AT1 blockade while doubling the risk.
• Option D: Option D is incorrect because losartan's uricosuric property does not justify adding it as a second RAAS inhibitor — the pharmacological concern is the AT1 blockade component, not the uricosuric component.
• Option E: Option E is incorrect because the combination of sacubitril/valsartan plus a second RAAS inhibitor is contraindicated regardless of whether spironolactone is present or absent.

ANSWER: A

Rationale:

R.K.'s regimen represents the four pillars of HFrEF GDMT plus volume management. Sacubitril/valsartan: PARADIGM-HF demonstrated a 20% reduction in the composite of cardiovascular death and HF hospitalization compared to enalapril, establishing sacubitril/valsartan as the preferred RAAS inhibitor strategy in symptomatic HFrEF. Carvedilol: US Carvedilol trial and COPERNICUS demonstrated survival benefit in HFrEF including severe HFrEF (NYHA III–IV); COPERNICUS showed 35% reduction in all-cause mortality. Spironolactone: RALES demonstrated 30% reduction in all-cause mortality in severe HFrEF (NYHA III–IV) on background ACEi and loop diuretic. Furosemide: manages volume overload; no specific mortality reduction evidence but essential for symptomatic control. Amlodipine: V-HeFT III demonstrated hemodynamic neutrality in HFrEF — it does not contribute to HFrEF mortality reduction but is safe for blood pressure control. Option B: Option C: Option D: Option E:

• Option B: Option B is incorrect because amlodipine and furosemide do not have mortality reduction evidence equivalent to the four GDMT pillars.
• Option C: Option C is incorrect because spironolactone's RALES evidence was in severe HFrEF; however, eplerenone's EMPHASIS-HF demonstrated benefit in mild HFrEF (NYHA II), expanding MRA use; the decision depends on functional class assessment, but the statement that spironolactone should be discontinued is an overstatement.
• Option D: Option D is incorrect because no trial has demonstrated bisoprolol superiority over carvedilol in HFrEF; both are guideline-recommended with similar evidence levels.
• Option E: Option E is incorrect because TRANSFORM-HF did not meet its primary endpoint — torsemide did not demonstrate superiority over furosemide for all-cause mortality. CASE 4 — S.W. is a 55-year-old woman with confirmed primary aldosteronism from bilateral adrenal hyperplasia (ARR 42; 24-hour urine aldosterone elevated; adrenal CT showing bilateral nodular hyperplasia without a dominant adenoma). BP is 172/102 mmHg. She has no CKD (eGFR 82 mL/min/1.73m²) and potassium is 3.1 mEq/L.

ANSWER: D

Rationale:

Spironolactone is the drug of choice for bilateral adrenal hyperplasia-type primary aldosteronism. As a competitive MR antagonist, it directly blocks the aldosterone receptor driving sodium retention, potassium wasting, volume expansion, and hypertension. By targeting the primary pathophysiological driver, it corrects all three abnormalities simultaneously — blood pressure, hypokalemia, and suppressed renin. Standard practice is to start at 25 mg daily and titrate upward to achieve blood pressure control and potassium normalization, often requiring 100–200 mg in bilateral hyperplasia. S.W.'s potassium of 2.8 mEq/L requires correction — spironolactone itself will raise potassium as MR blockade takes effect, but supplemental potassium may be needed initially while the MR blockade is being established. Monitor potassium at 2 weeks. Option A: Option B: Option C: Option E:

• Option A: Option A is incorrect because amiloride blocks ENaC directly and independently of aldosterone; in primary aldosteronism the pathology involves autonomous aldosterone activating the MR throughout the cardiovascular system, not just the kidney; amiloride provides potassium-sparing benefit and some BP reduction but does not provide the full systemic MR antagonism that spironolactone does; amiloride is a second-line option when spironolactone adverse effects are intolerable.
• Option B: Option B is incorrect because eplerenone is approximately 40–50x less potent than spironolactone at the MR per milligram — in bilateral adrenal hyperplasia with severe hypertension and profound hypokalemia, eplerenone at typical doses may provide insufficient MR blockade; it is used when spironolactone adverse effects are intolerable.
• Option C: Option C is incorrect because FIDELIO-DKD and FIGARO-DKD studied finerenone in diabetic CKD, not primary aldosteronism; finerenone does not have a primary aldosteronism evidence base.
• Option E: Option E is incorrect because furosemide before MRA initiation is not standard practice and would worsen hypokalemia; the MRA is the primary treatment.

ANSWER: B

Rationale:

Spironolactone's sex hormone adverse effects arise from its non-selective receptor binding profile. In addition to competitively antagonizing the mineralocorticoid receptor, spironolactone binds androgen receptors (as an antagonist, blocking testosterone effects) and progesterone receptors. In women, androgen receptor blockade can cause breast tenderness and menstrual irregularities; progesterone receptor binding further affects reproductive hormonal signaling. In men, anti-androgenic effects produce gynecomastia and sexual dysfunction. These are mechanism-based, predictable adverse effects. Eplerenone is a selective MRA that was specifically designed to avoid androgen and progesterone receptor binding — it has essentially no clinically significant affinity for these receptors, eliminating sex hormone adverse effects entirely. Because eplerenone is approximately 40–50x less potent than spironolactone at the MR on a per-milligram basis, doses of 50 mg twice daily may be required to achieve MR blockade equivalent to spironolactone 100 mg daily in primary aldosteronism. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect because spironolactone does not act as a progesterone agonist in breast tissue; the mechanism involves anti-androgenic effects (blockade of androgen receptors) and progesterone receptor interaction, and CCBs do not address MR blockade.
• Option C: Option C is incorrect because spironolactone does not elevate prolactin through dopamine receptor inhibition; prolactin elevation is not the mechanism of breast tenderness; amiloride does not provide equivalent MR blockade.
• Option D: Option D is incorrect because the adverse effects are pharmacologically predictable mechanism-based effects, not idiosyncratic immune reactions; pharmacological substitution with a selective MRA is available and appropriate.
• Option E: Option E is incorrect because these adverse effects are ongoing pharmacological effects that do not spontaneously resolve without a change in therapy.

ANSWER: E

Rationale:

S.W. requires additional antihypertensive therapy beyond eplerenone. Amlodipine is the optimal addition because it works through an entirely independent mechanism — vascular L-type calcium channel blockade — providing arteriolar dilation and BP reduction without any pharmacological overlap with eplerenone's MR blockade or any effect on potassium. In a patient whose potassium is already being actively managed by an MRA, potassium-neutral agents are preferable additions. Amlodipine has no effect on the renin-aldosterone axis, no potassium effect, no renal dose adjustment requirement, and no clinically significant interaction with eplerenone. Option A: Option B: Option C: Option D:

• Option A: Option A is incorrect because adding an ACEi to a patient already on an MRA creates dual RAAS-potassium-retaining combination; while ACEi plus MRA is used in some HF settings, it requires careful potassium monitoring and is not the standard add-on strategy for primary aldosteronism without HF.
• Option B: Option B is incorrect because while losartan has uricosuric properties, this is not the basis for selecting it in primary aldosteronism; and adding an ARB to a patient on an MRA requires careful hyperkalemia monitoring.
• Option C: Option C is incorrect because beta-blockers do not reduce autonomous aldosterone secretion from bilateral adrenal hyperplasia — the aldosterone is secreted autonomously, independent of the RAAS; reducing renin does not suppress autonomous adrenal aldosterone production.
• Option D: Option D is incorrect because amiloride plus eplerenone would create dual ENaC-pathway blockade with significant hyperkalemia risk; the combination also does not address the vascular resistance component of her hypertension.

ANSWER: C

Rationale:

Aldosterone has well-characterized direct organ effects beyond blood pressure elevation. Through MR activation in cardiac fibroblasts, aldosterone promotes collagen synthesis and myocardial fibrosis — contributing to LVH and diastolic dysfunction independent of the hemodynamic load. In the kidney, aldosterone activates MR in podocytes and tubular cells, promoting inflammatory mediator release and contributing to glomerular injury reflected in microalbuminuria. These non-hemodynamic effects explain why patients with primary aldosteronism have higher rates of cardiac fibrosis, LVH, and cardiovascular events compared to essential hypertension patients with equivalent blood pressure levels — the excess aldosterone causes end-organ damage through mechanisms beyond the pressure it generates. MR blockade with eplerenone addresses both the hemodynamic (BP reduction) and non-hemodynamic (anti-fibrotic, anti-inflammatory) pathological mechanisms. The EMPHASIS-HF trial (eplerenone in HFrEF with mild symptoms) demonstrated cardiovascular event reduction through MR blockade that extended beyond blood pressure effects, consistent with aldosterone's direct organ pathology. For S.W., continued MR blockade is pharmacologically justified as the mechanism targeting the actual pathophysiology of aldosterone excess, not merely its pressure consequence. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect because blood pressure control alone does not fully reverse aldosterone-mediated fibrotic effects; the rate and completeness of regression depend on removing the MR-mediated fibrotic stimulus.
• Option B: Option B is incorrect because aldosterone's effects are not purely hemodynamic; the non-hemodynamic fibrotic and inflammatory mechanisms are distinct from blood pressure effects.
• Option D: Option D is incorrect because LVH and microalbuminuria can regress with appropriate therapy — they are not irreversible.
• Option E: Option E is incorrect because hypokalemia is not the primary mechanism of aldosterone-related LVH and microalbuminuria; MR-mediated fibrotic effects are the primary driver. CASE 5 — T.B. is a 58-year-old man with hypertension, type 2 diabetes (HbA1c 8.2%), recurrent gout (four episodes in three years; uric acid 9.4 mg/dL; on allopurinol 300 mg daily), and stage 3a CKD (eGFR 58 mL/min/1.73m², UACR 95 mg/g). BP is 162/96 mmHg. He has no history of heart failure.

ANSWER: A

Rationale:

T.B. has three simultaneous conditions that pharmacological agent selection can address: hypertension, gout, and diabetic CKD with albuminuria requiring RAAS-mediated renoprotection. Losartan is uniquely positioned to address all three. As an ARB it provides RAAS inhibition with renoprotective and antiproteinuric effects in diabetic CKD — established by the RENAAL trial (losartan in type 2 diabetic nephropathy) and IDNT. As an ARB with unique URAT1-inhibiting uricosuric properties (its active metabolite EXP3174 inhibits URAT1 in the proximal tubule), losartan actively lowers serum uric acid, complementing allopurinol's xanthine oxidase inhibition through a different and additive mechanism. This combination of RAAS inhibition, renoprotection, and uricosuric activity makes losartan the optimal first agent in this multimorbid patient. A second agent (likely amlodipine as a uric acid-neutral CCB) can be added if additional BP control is needed. Option B: Option C: Option D: Option E:

• Option B: Option B is incorrect because chlorthalidone raises serum uric acid and would worsen gout despite allopurinol; it should be avoided in this patient if alternatives with superior uric acid profiles are available.
• Option C: Option C is incorrect because while amlodipine is uric acid-neutral, it does not provide RAAS-mediated renoprotection for diabetic CKD with albuminuria; losartan addresses both goals simultaneously.
• Option D: Option D is incorrect because loop diuretics raise serum uric acid through the same proximal tubular secretion competition mechanism as thiazides; furosemide would worsen gout and has no outcome evidence for diabetic nephropathy renoprotection.
• Option E: Option E is incorrect because beta-blockers do not have a uricosuric mechanism through URAT1; this pharmacological rationale is not established.

ANSWER: D

Rationale:

T.B. needs a second antihypertensive that is uric acid-neutral (given his gout), does not worsen potassium (currently 4.5 mEq/L on losartan with CKD and diabetes), and is safe at his eGFR. Amlodipine satisfies all three constraints: it has no effect on uric acid metabolism (completely uric acid-neutral); it requires no renal dose adjustment at any eGFR (hepatic elimination); it has no effect on potassium; and the CCB plus RAAS inhibitor combination has strong evidence from ACCOMPLISH for cardiovascular event reduction in high-risk patients. Amlodipine is the pharmacologically clean second agent for this multimorbid patient. Option A: Option B: Option C: Option E:

• Option A: Option A is incorrect because chlorthalidone raises serum uric acid through tubular secretion competition and volume contraction-mediated URAT1 reabsorption enhancement; this patient has active recurrent gout and adding a thiazide risks triggering another flare despite allopurinol.
• Option B: Option B is incorrect for the same reason — HCTZ raises uric acid through the same mechanism.
• Option C: Option C is incorrect because spironolactone with potassium at 4.5 mEq/L on losartan in a patient with CKD and diabetes creates significant hyperkalemia risk; spironolactone is appropriate as a fourth-line agent.
• Option E: Option E is incorrect because loop diuretics raise serum uric acid through the same proximal tubular mechanism as thiazides and would worsen gout; eGFR 58 does not require a loop diuretic.

ANSWER: B

Rationale:

CCB-associated peripheral edema arises from preferential arteriolar dilation without matched venodilation — capillary hydrostatic pressure rises in dependent tissues. For T.B. specifically, losartan must be maintained (it provides RAAS-mediated renoprotection for his diabetic CKD with albuminuria, plus uricosuric benefit that would be lost if it were discontinued). The management strategy should address the CCB edema while preserving losartan. Switching to felodipine, which has higher vascular selectivity than amlodipine and produces less peripheral edema at equivalent antihypertensive doses, directly addresses the mechanism — less preferential arteriolar dilation means less capillary hydrostatic pressure imbalance. Maintaining losartan at maximum dose preserves its venodilatory and efferent arteriolar dilating effects that partially counteract CCB edema. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect because replacing losartan with chlorthalidone removes the RAAS-mediated renoprotective and uricosuric benefits that are specifically important for this patient; chlorthalidone would also raise uric acid; and diuretics do not mechanistically address the capillary hydrostatic pressure imbalance causing CCB edema.
• Option C: Option C is incorrect because furosemide targets sodium-mediated volume overload; CCB edema is not sodium-mediated — loop diuretics have limited efficacy for this edema type.
• Option D: Option D is incorrect because all ARBs provide equivalent venodilation through AT1 blockade; there is no clinically established differential venodilatory effect between valsartan and losartan.
• Option E: Option E is incorrect because spironolactone does not specifically counteract the hemodynamic capillary pressure mechanism of CCB edema; the sodium-retaining component of CCB edema (if any) is not aldosterone-mediated in this context.

ANSWER: E

Rationale:

Finerenone initiation requires a structured pre-initiation assessment. The FIDELIO-DKD and FIGARO-DKD trials used specific entry criteria that reflect clinical safety requirements: potassium must be 4.8 mEq/L or below before initiating finerenone — above this level the risk of hyperkalemia from adding an MRA to background RAAS inhibition in CKD exceeds the cardiorenal benefit threshold; eGFR must be above approximately 25 mL/min/1.73m2 — below this threshold finerenone safety data are limited and the benefit-risk ratio is unclear; background RAAS inhibition should be optimized before adding finerenone since it was studied in the context of maximal tolerated RAAS inhibitor doses (T.B. is already on losartan 100 mg — appropriate). After initiation, potassium and eGFR must be rechecked at 4 weeks. The dose titration protocol from the trials: start at 10 mg once daily; if potassium remains 4.8 mEq/L or below at 4 weeks, titrate to 20 mg once daily for maximum cardiorenal benefit. T.B.'s potassium (4.3 mEq/L at last check) and eGFR (58 mL/min/1.73m2) make him an appropriate candidate. Option A: Option B: Option C: Option D:

• Option A: Option A is incorrect because potassium thresholds absolutely apply — the hyperkalemia risk of finerenone in CKD on RAAS inhibition is real and the 4.8 mEq/L threshold is a key safety criterion.
• Option B: Option B is incorrect because eGFR must also be checked; the combination of low eGFR and RAAS inhibition substantially increases finerenone hyperkalemia risk.
• Option C: Option C is incorrect because finerenone does require pre-initiation assessment and ongoing monitoring in CKD — it reduces GFR modestly in the first weeks (hemodynamic effect) and can cause hyperkalemia.
• Option D: Option D is incorrect because UACR threshold is part of the indication but does not replace the potassium and eGFR safety assessment. CASE 6 — V.N. is a 62-year-old woman with hypertension on lisinopril 40 mg, amlodipine 10 mg, and chlorthalidone 25 mg daily. BP is 168/98 mmHg despite confirmed adherence. Secondary causes have been excluded. Plasma renin activity is 0.4 ng/mL/hr (suppressed). Potassium is 3.4 mEq/L. ARR is elevated. eGFR is 66 mL/min/1.73m².

ANSWER: C

Rationale:

V.N.'s low PRA of 0.4 ng/mL/hr is clinically important context for the spironolactone decision. PATHWAY-2 demonstrated that the systolic blood pressure reduction from spironolactone in resistant hypertension was greatest in patients with the lowest plasma renin activity — the relationship between low PRA and MRA response was one of the most clinically informative findings in the trial. Low PRA indicates renin suppression from volume expansion, consistent with relative aldosterone excess (even without meeting formal primary aldosteronism criteria). Adding a mineralocorticoid receptor antagonist directly targets this volume-dependent aldosterone-mediated pathophysiology. Her potassium of 3.7 mEq/L is low-normal — the thiazide diuretic is likely driving potassium loss that spironolactone will partially offset. The combination of MRA plus thiazide often produces near-neutral potassium effects, though monitoring is essential. Starting dose is 25 mg daily, not 100 mg. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect because potassium below 4.0 mEq/L is not a contraindication to spironolactone initiation — it is actually favorable; the contraindication threshold is generally potassium above 4.5 mEq/L in the context of CKD.
• Option B: Option B is incorrect because low PRA in the context of resistant hypertension does not mandate formal primary aldosteronism evaluation before MRA therapy; PATHWAY-2 enrolled patients without formal PA diagnosis; most patients with low PRA resistant hypertension benefit from MRA regardless of whether formal PA criteria are met.
• Option D: Option D is incorrect because standard starting dose in resistant hypertension is 25 mg daily with gradual titration if needed.
• Option E: Option E is incorrect because thiazide plus MRA is a rational combination — the thiazide's potassium-wasting effect and the MRA's potassium-retaining effect partially offset each other; this is one reason the combination is pharmacologically complementary, not dangerous.

ANSWER: C

Rationale:

A creatinine rise of this magnitude (eGFR 68 → 52, approximately 24% fall) when adding an MRA to existing diuretic and RAAS inhibitor therapy requires careful interpretation rather than automatic drug discontinuation. Modest, non-progressive creatinine rises of up to 30–40% above baseline are expected and accepted when RAAS-class drugs (including MRAs) are added — they reflect hemodynamic reduction in intraglomerular pressure through efferent arteriolar dilation, reducing the glomerular filtration fraction. This is a pharmacological mechanism, not nephrotoxicity. The key clinical questions are: Is this progressive or stable? Is the patient volume-depleted (from chlorthalidone plus the new MRA reducing aldosterone-driven sodium retention)? Orthostatic symptoms, weight loss, or excessive thirst would suggest volume depletion. Holding chlorthalidone temporarily and rechecking creatinine in 1–2 weeks is the appropriate diagnostic and therapeutic maneuver. If creatinine stabilizes and the patient has no symptoms of AKI, spironolactone can be continued with monitoring. However, a rise exceeding 30–40% or continued progression warrants dose reduction or drug discontinuation. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect because spironolactone does not cause acute tubular necrosis; the creatinine rise reflects hemodynamic intraglomerular pressure reduction, not nephrotoxicity.
• Option B: Option B is incorrect because a 24% creatinine rise in the context of RAAS-class drug initiation does not mandate immediate discontinuation; the acceptable threshold for hemodynamic creatinine rise is generally up to 30–40%.
• Option D: Option D is incorrect because renal artery stenosis is not the likely mechanism here; the creatinine rise occurred in the context of adding an MRA to existing diuretic and RAAS therapy, consistent with hemodynamic intraglomerular pressure reduction.
• Option E: Option E is incorrect because IV fluid resuscitation and complete medication hold are not indicated; this is a monitored hemodynamic response requiring conservative management.

ANSWER: D

Rationale:

Chlorthalidone is the most likely culprit for V.N.'s new-onset hyperuricemia and acute gout. Thiazide-type diuretics cause hyperuricemia through two well-established complementary mechanisms: (1) competition with uric acid at organic anion transporters (OAT1, OAT3) in the proximal tubule — thiazide molecules occupy these transporters, reducing uric acid secretion into the tubular lumen and raising serum uric acid; (2) volume contraction from natriuresis activates compensatory proximal tubular sodium reabsorption, and uric acid follows sodium reabsorption via the URAT1 transporter — enhanced urate reabsorption further raises serum uric acid. Although the chlorthalidone dose was reduced from 25 to 12.5 mg, this mechanism continues at lower doses. The appropriate management combines treating the acute gout episode (colchicine, NSAIDs, or glucocorticoids) with consideration of switching lisinopril to losartan — losartan's unique URAT1-inhibiting uricosuric property would partially offset chlorthalidone's urate-reabsorption enhancement, a pharmacologically targeted solution. Option A: Option B: Option C: Option E:

• Option A: Option A is incorrect because spironolactone does not inhibit xanthine oxidase; that mechanism belongs to allopurinol and febuxostat.
• Option B: Option B is incorrect because lisinopril (ACE inhibitors) does not have a URAT1-promoting mechanism that raises uric acid.
• Option C: Option C is incorrect because amlodipine has no effect on proximal tubular uric acid handling; DHP CCBs act on vascular smooth muscle calcium channels.
• Option E: Option E is incorrect because spironolactone does not affect uric acid through plasma protein displacement; this mechanism is not established.

ANSWER: B

Rationale:

This four-drug regimen represents one of the most pharmacologically elegant constructions in clinical hypertension pharmacology because each agent addresses a distinct mechanism while creating complementary interactions. Losartan: AT1 receptor blockade reduces angiotensin II-mediated vasoconstriction and aldosterone secretion; uniquely provides URAT1-mediated uricosuric benefit complementary to the other agents. Chlorthalidone: NCC inhibition produces natriuresis and volume reduction; this volume depletion activates the RAAS (raising renin and angiotensin II), which enhances losartan's antihypertensive efficacy by providing more substrate for AT1 blockade; simultaneously causes kaliuresis that spironolactone offsets. Spironolactone: MR blockade directly targets the volume-dependent aldosterone-mediated physiology driving this patient's resistant hypertension (low PRA, PATHWAY-2 evidence); it also provides potassium conservation that partially neutralizes chlorthalidone's potassium wasting — a metabolic complementarity. Amlodipine: L-type vascular calcium channel blockade produces peripheral arteriolar vasodilation through a completely RAAS-independent mechanism; it is potassium-neutral; it contributes antihypertensive effect through the component of vascular tone that is not aldosterone-dependent or volume-dependent. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect because amlodipine does not work through the RAAS pathway; it is RAAS-independent.
• Option C: Option C is incorrect because losartan plus spironolactone is not dual RAAS inhibition in the harmful sense (ONTARGET-type); MRA plus ARB is used in HFrEF with monitoring and is safe with appropriate potassium monitoring.
• Option D: Option D is incorrect because amiloride provides ENaC blockade but not MR blockade; spironolactone's MR antagonism has specific value in this resistant hypertension context (PATHWAY-2), and it does not have an absolute contraindication with ARB therapy.
• Option E: Option E is incorrect because amlodipine and thiazide diuretics work through entirely different mechanisms — arteriolar calcium channel blockade versus NCC inhibition and volume reduction — and are not redundant; their combination is additive. CASE 7 — W.H. is a 78-year-old woman with long-standing hypertension and stage 3b CKD (eGFR 34 mL/min/1.73m²). She has no diabetes, no heart failure, and no proteinuria. BP is 174/78 mmHg (pulse pressure 96 mmHg). She is on no antihypertensive therapy. Potassium is 4.6 mEq/L and sodium is 139 mEq/L.

ANSWER: E

Rationale:

W.H. presents multiple converging factors that inform antihypertensive selection. Her ISH with wide pulse pressure reflects aortic stiffness — the pathophysiology that makes DHP CCBs and thiazide-type diuretics the preferred agents in elderly ISH. However, her CKD stage 3b (eGFR 34 mL/min/1.73m2) creates a critical constraint: at this eGFR, thiazide-type diuretics have substantially reduced efficacy (decreased tubular secretion limits drug delivery to NCC, and reduced nephron mass limits the natriuretic response). If a diuretic is needed, torsemide is the appropriate choice — its predictable 80% oral bioavailability and predominantly hepatic metabolism make it reliable at low eGFR. Her small body habitus (52 kg) and high fluid intake (2 liters/day) create significant risk for thiazide-associated hyponatremia if a thiazide were used, reinforcing the preference for a non-thiazide strategy. Amlodipine is the most appropriate initial agent: mechanistically aligned with ISH pathophysiology, safe at any eGFR (hepatic elimination), no potassium effect (potassium already at 4.6 mEq/L), and strong ISH outcome trial support. Option C is accurate but less complete than E — C does not address the hyponatremia risk from her specific body composition and fluid intake. Option A: Option B: Option D:

• Option A: Option A is incorrect because age is not a contraindication to antihypertensive therapy; HYVET definitively established benefit in patients aged 80 and above.
• Option B: Option B is incorrect because DHP CCBs, RAAS inhibitors, and other classes are all used in CKD stage 3b; loop diuretics are not the only safe antihypertensive at eGFR below 40.
• Option D: Option D is incorrect because RAAS inhibition without proteinuria in CKD stage 3b does not have a mandatory first-line designation; the absence of albuminuria removes the specific renoprotective compelling indication.

ANSWER: C

Rationale:

At eGFR 32 mL/min/1.73m2, the appropriate diuretic choice transitions from thiazide-type to loop diuretics. Torsemide is preferred over furosemide for outpatient use due to its approximately 80% predictable oral bioavailability compared to furosemide's variable 10–100% absorption, and its once-daily dosing suitability. The loop diuretic will also modestly address any sodium retention component of the amlodipine-associated edema. Critically, close sodium monitoring is essential in this patient — her small body size (52 kg), high fluid intake (2 liters/day), and now combined arteriolar vasodilation from amlodipine with diuretic-driven volume contraction create compounded risk for hyponatremia and orthostatic hypotension. Sodium should be checked at 2 weeks after initiation. Option E is not wrong — losartan is a reasonable second agent — but C is more pharmacologically complete given the diuretic indication at this eGFR and the edema concern. Option A: Option B: Option D:

• Option A: Option A is incorrect because chlorthalidone has substantially reduced efficacy at eGFR 32 — its natriuretic effect depends on adequate tubular secretion for NCC delivery, which is impaired at this eGFR; additionally, chlorthalidone's long half-life would pose greater hyponatremia risk than torsemide in this high-risk patient.
• Option B: Option B is incorrect because spironolactone with potassium at 4.5 mEq/L in CKD stage 4 (borderline) creates significant hyperkalemia risk when combined with a RAAS inhibitor if one is added; it is not appropriate as a second agent here.
• Option D: Option D is incorrect because combining two CCBs (non-DHP plus DHP) would produce additive vasodilation without the pharmacological complementarity of different drug classes; it is not a recommended combination strategy.

ANSWER: C

Rationale:

The combination of losartan plus torsemide in CKD is not contraindicated — these classes are frequently used together in clinical practice with appropriate monitoring. The key monitoring required after adding losartan to this patient's regimen addresses three parameters simultaneously. Potassium: losartan reduces aldosterone through AT1 blockade, reducing collecting duct potassium secretion and raising potassium; her potassium of 3.8 mEq/L is low-normal (torsemide is driving some potassium loss); the RAAS inhibitor will tend to raise it toward normal, which is beneficial; monitor at 2 weeks. Creatinine: losartan dilates efferent arterioles (RAAS-mediated), reducing intraglomerular pressure; a modest hemodynamic creatinine rise of up to 30% is expected and acceptable; monitor at 2 weeks. Sodium: already at 134 mEq/L in a high-risk patient (small body, high fluid intake, now on a loop diuretic plus arteriolar vasodilator); adding losartan does not directly cause hyponatremia but the overall volume state should be monitored; check sodium at 2 weeks. Option A: Option B: Option D: Option E:

• Option A: Option A is incorrect because monitoring is absolutely required after adding losartan to a CKD patient on a loop diuretic; potassium, creatinine, and electrolytes require surveillance.
• Option B: Option B is incorrect because losartan plus torsemide in CKD is not contraindicated; these classes are used together safely with monitoring in routine clinical practice.
• Option D: Option D is incorrect because RAAS inhibitors cause potassium retention (not hypokalemia) — supplemental potassium is not needed and could worsen hyperkalemia risk.
• Option E: Option E is incorrect because pre-emptive torsemide dose reduction before adding an RAAS inhibitor is not standard practice; the monitoring protocol after initiation is the appropriate management.

ANSWER: B

Rationale:

SPRINT demonstrated that intensive systolic targets (less than 120 mmHg vs. less than 140 mmHg) reduced major cardiovascular events by approximately 25% and all-cause mortality by approximately 27% in adults with high cardiovascular risk but without diabetes. The elderly subgroup (over 75) in SPRINT showed similar or greater absolute benefit. However, SPRINT also showed higher rates of AKI, electrolyte abnormalities, syncope, and orthostatic hypotension in the intensive arm. For W.H. specifically, her CKD with declining eGFR (28 mL/min/1.73m2), small body size, high fluid intake, existing sodium at 136 mEq/L, and pulse pressure physiology (diastolic already at 68 mmHg) create specific risks with intensive target pursuit. A systolic target of 130–140 mmHg represents a balanced individualized goal — meaningfully below the 160+ mmHg she presented with, providing substantial cardiovascular event reduction while avoiding the AKI, electrolyte disturbance, and orthostatic fall risks that aggressive intensification would create. Guideline recommendations since SPRINT support individualized target-setting in elderly patients with frailty or advanced CKD. Option A: Option C: Option D: Option E:

• Option A: Option A is incorrect because applying intensive targets to all elderly patients without individualization ignores the SPRINT-identified risks of AKI, electrolyte disturbance, and falls in high-risk subgroups; guideline interpretation requires individualization.
• Option C: Option C is incorrect because SPRINT excluded patients with eGFR below 20, not below 45; W.H.'s eGFR of 28 is within the SPRINT enrollment range technically, but her clinical risk profile requires individualized target-setting rather than automatic application.
• Option D: Option D is incorrect because SPRINT did not demonstrate that intensive targets are harmful in all patients over 75; the elderly subgroup showed benefit; the concern is individualization, not class contraindication.
• Option E: Option E is incorrect because SPRINT did enroll patients with CKD (eGFR above 20); the absence of CKD-specific outcome data is not the reason for caution — rather, W.H.'s specific frailty risk factors require individualized goal-setting.